SELLAS Life Sciences announces closing of $24.2 million public offering
SELLAS Life Sciences announced the closing of its underwritten public offering of 6,845,000 shares of common stock, 4,675,000 pre-funded warrants exercisable for shares of common stock, and accompanying common stock warrants to purchase an aggregate of 11,520,000 shares of common stock. July 16, 2018